SYNGENE Q3 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹853.5 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
₹232 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene delivered Q3 FY24 results broadly in line with muted expectations, with revenue from operations at INR 834 crore (+9% YoY) and PAT at INR 115 crore (+4% YoY), while EBITDA remained flat at INR 232 crore. The underperformance versus historical growth rates stems from U.S. biotech funding normalization impacting Discovery services—a headwind management characterizes as transient. Management sees stabilization signals including an uptick in biotech RFPs during Q3 and sustained demand from Big Pharma, positioning Q4 to be sequentially stronger though facing a tough YoY comparison due to Zoetis project base effect. Full-year guidance revised to double-digit growth from mid-teens. The Stelis Biologics facility acquisition completed December 1, 2023, will require revalidation before contributing revenue in H2 FY25. The CDMO segment is now ~40% of revenue and growing at 20-25%, providing strategic resilience. The primary risk remains the timing uncertainty of biotech funding recovery and margin pressure from fixed Discovery services costs.
Colored figures show movement against the previous available record.
Guidance to track
- Given slower Q3 growth in Discovery services, management now expects full-year revenue growth to land in double-digits rather than the previously guided mid-teens range.
- Q4 is anticipated to deliver better revenue than Q3 on a sequential basis, potentially marking one of the largest revenue quarters of FY24.
- Full-year CapEx guidance lowered to approximately $60 million from prior guidance of $80 million, moderated to balance research business investments with revenue growth visibility.
- The recently acquired Stelis Biopharma facility requires revalidation and upgrading through calendar 2024, with commercial production expected to begin in the second half of next financial year.
Risks flagged
- U.S. biotech VC funding normalization may take 1-3 more quarters to work through the system before Discovery services growth recovers. Management acknowledged uncertainty on exact timing of recovery.
- The Zoetis project was fully operational in Q4 FY23, creating a tough year-on-year comparison for Q4 FY24. Analyst Shaleen Kumar projected potential negative to low single-digit YoY growth for Q4, which management did not explicitly refute.
- Operating EBITDA margin declined 200 bps YoY to 27% as fixed costs in Discovery services remain while revenue growth slows. Margin dilution from Stelis facility pre-operative costs will be fully reflected when the plant goes live.
- CFO explicitly flagged that lower cash balances following the Stelis acquisition payment will result in reduced interest income, impacting PAT relative to prior periods despite strong underlying business performance.
Key quotes
- Trends outside of biotech, so Big Pharma, animal health, big biotech, other regions of the world other than the U.S., are much less affected. As I look across the global industry and at our peer groups, you can see these patterns are pretty widely reported, and I think that sort of suggests they're well understood.
- We consider the slower growth in Discovery services as transient, and while the exact timing of recovery is uncertain, we will watch the uptick in RFP inflow that Jonathan mentioned closely in the coming weeks as an early indicator for increased growth in the next financial year.
- We've only—we're only just digesting the Stelis acquisition. We've got a busy year ahead of turning that facility around, so that it's operating as an antibody plant rather than as a vaccines plant. And then simultaneously with that, we're out trying to sell that capacity.
Research modules